Skip to main content

iwCLL 2023 Main banner

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Jacqueline C. Barrientos, MD, MS

Mount Sinai Comprehensive Cancer Center

N/A

Poster(s):

1204 - Real-World Characteristics and Outcomes of Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Long-Term Ibrutinib: Results From the Prospective, Observational informCLL Registry
1226 - Outcomes of Tixagevimab/cilgavimab pre-exposure prophylaxis in Chronic lymphocytic leukemia patients- a single center experience
2024 - Phase 1/2 Study of Zilovertamab and Ibrutinib: Durable responses suggest a novel mechanism for synthetic lethality in TP53 aberrant disease.
3003 - COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)